鲁抗医药(600789.SH)发预减，预计2025年度归母净利润1.1亿元-1.45亿元，同比减少63.26%-72.13%

Group 1 - The company, Lu Kang Pharmaceutical (600789.SH), expects to achieve a net profit attributable to shareholders of the parent company between 110 million to 145 million yuan for the fiscal year 2025 [1] - This represents a decrease of 249.62 million to 284.62 million yuan compared to the previous year [1] - The year-on-year decline in net profit is projected to be between 63.26% to 72.13% [1]